Cambrex grants Zeria's Tillotts Pharma AG subsidiary exclusive, worldwide rights to use Cambrex's mesalamine-based technology to develop and commercialize products to treat IBD

Cambrex Corp.

U.S. / Tools, Services, and Manufacturing

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Zeria Pharmaceutical Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced